Skip to content Skip to footer
Subscribe Now
Eli lilly
NEWS

Eli Lilly Reports P-IIIb (TOGETHER-PsA) Trial on Taltz + Zepbound for Psoriatic Arthritis and Obesity or Overweight

Shots: Eli Lilly has reported P-IIIb (TOGETHER-PsA) trial assessing concomitant Taltz (ixekizumab) & Zepbound (tirzepatide) vs Taltz alone in 271 adults with active PsA & obesity or overweight with ≥1 weight-related condition Trial met its 1EP, with 31.7% of pts achieving ACR50 & ≥10% weight loss at Wk. 36 vs 0.8%, & met a key…
January 9, 2026

Read more

INSIGHTS+

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2025 (Part 01) 

Shots:    Lilly leads with precision and purpose with 45 deals totaling $21.22B in 2025, focusing on platform-driven, science-led partnerships across oncology, gene therapy, RNA editing, and AI-enabled discovery while building durable innovation engines rather than chasing short-term wins  Strategic dealmaking over sheer volume is evident in partnerships like precision oncology with Scorpion Therapeutics and CNS delivery with Sangamo, structured to…
January 8, 2026

Read more

NEWS

InduPro Therapeutics Collaborates with Eli Lilly in ~$950M Oncology Therapeutic Discovery Deal

Shots: InduPro has entered into a global strategic collaboration & licensing agreement with Eli Lilly to discover novel oncology treatments using InduPro’s proximity-guided platform Lilly will gain access to InduPro’s AI/ML-enabled MInt platform, with InduPro leading early discovery to identify co-target pairs & advance bispecific & multispecific antibody programs from the collaboration As per the…
January 8, 2026

Read more

NEWS

Eli Lilly to Acquire Ventyx for ~$1.2B

Shots: Eli Lilly has entered into a definitive agreement to acquire Ventyx, strengthening Lilly’s capabilities in inflammatory-mediated diseases As per the deal, Eli Lilly will acquire Ventyx for $14/share in an all-cash transaction, representing an aggregate equity value of ~$1.2B; closing is expected in H1’26 Ventyx is advancing a pipeline of oral small-molecule therapies, incl.…
January 8, 2026

Read more

NEWS

Nimbus Therapeutics and Eli Lilly Enter ~$1.3B Deal to Develop Oral Metabolic Therapies

Shots: Nimbus has entered into a multi-year research collaboration & exclusive, worldwide license agreement with Eli Lilly to develop a novel oral treatment for obesity & other metabolic diseases Building on their prior AMPK cardiometabolic collaboration, Nimbus & Lilly have entered into a new partnership applying Nimbus’ computational chemistry & structure-based design to an…
January 7, 2026

Read more

NEWS

ABL Bio Secures Upfront Payment and Equity Investment from Lilly to Accelerate Grabody Programs 

Shots: ABL Bio has secured a total of $55M, incl. $40M upfront & $15M in equity investment, from Eli Lilly under their ~$2.602B license, research & collaboration agreement Under the deal, ABL Bio & Eli Lilly are jointly advancing multiple therapeutic candidates across diverse modalities, leveraging ABL Bio’s Grabody platform for collaborative research & development…
December 29, 2025

Read more

Eli lilly
NEWS

Eli Lilly Reports Topline P-III (ATTAIN-MAINTAIN) Trial Results of Orforglipron for Weight Loss Maintenance 

Shots: Lilly's P-III trial assessed orforglipron vs PBO in maintaining weight loss in 376 adults with obesity/overweight & weight-related comorbidities who previously completed the initial treatment with Wegovy/Zepbound in the SURMOUNT-5 trial; NDA was submitted to FDA & received a US FDA’s CNPV Trial met its 1EP in SURMOUNT-5 pts at a weight plateau, showing superior…
December 19, 2025

Read more

Eli lilly
NEWS

Eli Lilly Reports P-III (BRUIN CLL-313) Trial Data on Jaypirca for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Shots: Eli Lilly has reported P-III (BRUIN CLL-313) trial data assessing Jaypirca (pirtobrutinib; 200mg, PO, QD; n=141) vs bendamustine + rituximab (n=141) in 282 treatment-naïve CLL/SLL pts without 17p deletions As of Jul 11, 2025, trial met its 1EP of improved IRC-assessed PFS by 80% with benefits seen across all high-risk subgroups & investigator assessments at…
December 10, 2025

Read more

Eli lilly
NEWS

Eli Lilly’s Jaypirca Receives the FDA Approval for R/R Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)

Shots: The US FDA has approved label expansion of Jaypirca (pirtobrutinib; 100 & 50mg) for the treatment of adults with r/r CLL/SLL who were previously treated with a covalent BTK inhibitor & converted the accelerated approval of Dec 2023 to a full approval Label expansion was based on the P-III (BRUIN CLL-321) study assessing Jaypirca…
December 4, 2025

Read more

Load more